Institute News

Overview: What the Genomics Institute Does

  • Genetic basis of common chronic diseases (most often cardiometabolic)
    • diabetes, cardiovascular disease, hyperlipidemia, hypertension, Alzheimer's/dementia, chronic kidney disease
  • Prediction of common diseases for patients and populations (using polygenic risk scores)
  • Prediction and mechanisms of common disease (using multi-omics)
  • Treatment of rare genetic disorders
  • Stem cell therapy pre-clinical development

Faculty of the Institute (2023)

Common Diseases

New

Therapy of Rare Disorders

New

 

30 Common Diseases Studied at the Genomics Institute

(and susceptibility to environmental and lifestyle factors)

>70 Publications/Year

Cardiovascular Vision
Atherosclerosis-Coronary Artery Diseases Diabetic Retinopathy
Aortic Valve Calcification-Aortic Stenosis Glaucoma
Congestive Heart Failure-Cardiomyopathy Retinopathy of Prematurity
Atrial Fibrillation Other
EKG-Arrhythmias Anemia and Red Blood Cell Disorders
Thrombosis Osteoporosis-Height
Stroke Breast Cancer
Metabolic COPD
Diabetes Types I and II Idiopathic Pulmonary Fibrosis
Insulin Resistance-Metabolic Syndrome COVID-19
Obesity Aging
Non-alcoholic Fatty Liver Disease Inflammation
Lipids CAD in RA and SLE
Polycystic Ovary Syndrome Dermatomyositis
Neurological Susceptibility to Environment
Alzheimer's Diet-Nutrition
Cognition Disorders Heavy Metals
Sleep Disorders Air Pollution
Renal Alcohol
Kidney Disease Stress
Hypertension Shift Work
(as of 8/18/2023: published in 2021 to present on 26; 2022 to the present on 24; 2023 to present on 16)

Rare Diseases and Related Therapies Studied at the Genomics Institute

Lysosomal Storage Diseases--------------------------> Drugs approved/under investigation/under development
Mucopolysaccharidosis type IH (Hurler syndrome) Adalimumab (Humira)
Mucopolysaccharidosis type IA (Scheie/Hurler Scheie syndrome) Adalimumab (Humira)
Mucopolysaccharidosis type II (Hunter syndrome) Adalimumab (Humira); Elaprase + Immune tolerance regimen
Mucopolysaccharidosis type III (Sanfilippo syndrome) Anakinra (Kineret); cannabidiol
Mucopolysaccharidosis type VI (Maroteaux-Lamy syndrome) Adalimumab (Humira)
Metachromatic Leukodystrophy Intrathecal SHP611
Fabry Disease -
Pompe Disease -
Niemann Pick Type C Intrathecal 2-hydroxypropyl-beta-cyclodextrin
Metabolic Bone Disease  
Osteopetrosis -
Neurologic Disorders  
Ataxia telangiectasia -
Pitt-Hopkins syndrome Antisense Oligonucleotide Therapy
Epilepsy Anti-epileptic therapy dose optimization
Skeletal Dysplasia  
Achondroplasia Vosoritide (Voxzogo); Recifercept
Hemoglobinopathies  
Sickle Cell Disease Decitabine-Tetrahydrouridine; GBT021601
Pediatric Cancer  
General (Children’s Oncology Group) Various COG protocols
COVID-19 in Pediatric Cancer Patients -
GENOMICS INSTITUTE PUBLICATIONS AND  PUBLICATIONS IN WORLD LEADING JOURNALS BY YEAR
World Leading Journals: NEJM, JAMA, The Lancet, Nature, Science, Cell, BMJ, Nature Genetics. 8/31/2023
C G I K L O P R T Y
Translational Genomics
Translational Genomics
Translational Genomics
Translational Genomics
Translational Genomics
Translational Genomics
Women's and Children's Health
Cancer Biology and Immunotherapeutics
Translational Genomics
Women's and Children's Health
Translational Genomics
Translational Genomics
Translational Genomics
Cancer Biology and Immunotherapeutics
Translational Genomics
Translational Genomics
Translational Genomics
Metabolic Diseases
Translational Genomics
Metabolic Diseases
Translational Genomics